NL-OMON43818已完成4 期
A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability ,PK of nintedanib in combination with pirfenidone.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Written informed consent consistent with ICH-GCP and local laws, signed prior to any study procedures being performed (including any required washout)
- •-Male or female patients aged greater than or equal to 40 years at visit 1.
- •-Idiopathic Pulmonary Fibrosis (IPF) diagnosis, based upon the ATS/ERS/JRS/ALAT 2011 guideline and confirmed by the investigator based on chest high resolution computed tomography (HRCT) scan performed within 12 months of visit 1
- •-FVC greater than or equal to 50% of predicted normal at visit 1
排除标准
- •-ALT, AST >1.5 fold upper limit of normal (ULN) at visit 1
- •-Total bilirubin; >1.5 fold ULN at visit 1
- •-Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC <0.7) at visit 1
- •-History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1
- •-Bleeding Risk: Known genetic predisposition to bleeding, Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin etc) or high dose antiplatelet therapy, History of haemorrhagic central nervous system event within 12 months prior to visit 1, History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1, International normalised ratio (INR),
- •Prothrombin time and partial thromboplastin time (PTT) > 150%
- •institutional ULN at visit 1
- •-Planned major surgery during the trial participation, including lung transplantation,major abdominal or major intestinal surgery.
- •-History of thrombotic event (including stroke and transient ischemic attack) within 12
- •months of visit 1
- •-Severe renal impairment (creatinine clearance<30 mL/min calculated by Cockroft-Gault formula at visit 1) or end stage renal disease requiering dialysis
- •-Treatment with NAC, prednisone >15 mg daily or >30 mg every 2 days OR equivalent;dose of other oral corticosteroids and/or fluvoxamine within 2 weeks of visit 2;-Treatment with azathioprine, cyclophosphamide, cyclosporine as well as any other;investigational drug within 8 weeks of visit 2;-Previous treatment with pirfenidone;-Permanent discontinuation of nintedanib in the past due to AEs considered drug-related;-Known hypersensitivity to nintedanib, pirfenidone, peanut or soya or to any of the;excipients;-A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial;-Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment;-Women who are pregnant, nursing, or who plan to become pregnant while in the trial.;-Women of childbearing potential not willing or able to use highly effective methods of;birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year;when used consistently and correctly for 28 days prior to and 3 months after nintedanib administration;-Patients not able to understand and follow study procedures including completion of selfadministered questionnaires without help;-Patients who require dose reduction and/or temporary interruption during the run-in;period with nintedanib 150 mg bid
- •-patients with underlying chronic liver disease (Child Pugh A,B or C impairment)
研究者
相似试验
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.135
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFMedDRA version: 18.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-FRBoehringer Ingelheim France136
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFMedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-DEBoehringer Ingelheim Pharma GmbH & Co.KG135
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-NLBoehringer Ingelheim bv135
进行中（未招募）
不适用
A trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) therapy on height velocity (Ht-V) in patients with idiopathic short stature in KoreaMedDRA version: 19.0Level: LLTClassification code 10066333Term: Idiopathic short statureSystem Organ Class: 100000004859Idiopathic short statureEUCTR2015-002613-30-Outside-EU/EEAovo Nordisk A/S54